TBO-309 is under clinical development by ThromBio Holdings and currently in Phase II for Acute Ischemic Stroke. According to GlobalData, Phase II drugs for Acute Ischemic Stroke have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TBO-309’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TBO-309 overview
TBO-309 is under development for the treatment of acute ischemic stroke (AIS). It is a new chemical entity. The drug candidate is administered as the intravenous infusion. The drug candidate targets PI3K-beta.
It was under development for the treatment of thrombosis.
ThromBio Holdings overview
ThromBio Holdings is a drug discovery company that focuses on the development of novel anti-thrombotic drugs for the treatments for stroke, specifically Acute Ischemic Stroke (AIS). The company is headquartered in Sydney, New South Wales, Australia.
For a complete picture of TBO-309’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
